106 related articles for article (PubMed ID: 464252)
1. [Heparin assay in plasma. Comparison of different methods (author's transl)].
Vinazzer H
Anaesthesist; 1979 Jun; 28(6):299-303. PubMed ID: 464252
[TBL] [Abstract][Full Text] [Related]
2. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
Bohner J; von Pape KW; Blaurock M
Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
[TBL] [Abstract][Full Text] [Related]
3. [Effect of heparin cofactor II on the antithrombin III activities measured by thrombin methods or factor Xa methods--fundamental studies and clinical studies using the plasma of pregnant women].
Akai Y; Shiga S; Tohyama K; Shimatsu A; Ichiyama S
Rinsho Byori; 2000 Sep; 48(9):867-71. PubMed ID: 11051806
[TBL] [Abstract][Full Text] [Related]
4. Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions.
Hoppensteadt DA; Walenga JM; Fareed J
Semin Thromb Hemost; 1985 Apr; 11(2):112-20. PubMed ID: 3898369
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
Harenberg J
J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
[TBL] [Abstract][Full Text] [Related]
6. The monitoring of heparin administration by screening tests in experimental dogs.
Mischke R; Jacobs C
Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
[TBL] [Abstract][Full Text] [Related]
7. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
[TBL] [Abstract][Full Text] [Related]
8. Multicenter evaluation of a chromogenic substrate method for photometric determination of prothrombin time.
Dati F; Barthels M; Conard J; Flückiger J; Girolami A; Hänseler E; Huber J; Keller F; Kolde HJ; Müller-Berghaus G
Thromb Haemost; 1987 Oct; 58(3):856-65. PubMed ID: 3433249
[TBL] [Abstract][Full Text] [Related]
9. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
10. An improved heparin assay which is insensitive to platelet factor 4.
Fickenscher K; Buckler U
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):873-8. PubMed ID: 2483705
[TBL] [Abstract][Full Text] [Related]
11. A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation.
Fischer AM; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1982 Apr; 47(2):104-8. PubMed ID: 6179182
[TBL] [Abstract][Full Text] [Related]
12. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J
Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
Meddahi S; Bara L; Fessi H; Samama MM
Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
[TBL] [Abstract][Full Text] [Related]
15. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues.
Jeske W; Fareed J
Semin Thromb Hemost; 1993; 19 Suppl 1():241-7. PubMed ID: 8362268
[TBL] [Abstract][Full Text] [Related]
16. The measurement of thrombin in clotting blood by radioimmunoassay.
Shuman MA; Majerus PW
J Clin Invest; 1976 Nov; 58(5):1249-58. PubMed ID: 993343
[TBL] [Abstract][Full Text] [Related]
17. [Prophylaxis of consumption coagulopathy in shock. Dependence of the effect of heparin on the activity of antithrombin III (author's transl)].
Bergmann H; Blauhut B; Necek S; Kramar H; Vinazzer H
Anaesthesist; 1980 Nov; 29(11):623-6. PubMed ID: 7457802
[TBL] [Abstract][Full Text] [Related]
18. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
19. The characteristics of anticoagulation by covalently immobilized heparin.
Miura Y; Aoyagi S; Kusada Y; Miyamoto K
J Biomed Mater Res; 1980 Sep; 14(5):619-30. PubMed ID: 7349668
[TBL] [Abstract][Full Text] [Related]
20. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]